• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chronos’ Huw Jones awarded 2016 Best European CEO in the Drug Discovery Industry

Chronos’ Huw Jones awarded 2016 Best European CEO in the Drug Discovery Industry

February 2, 2017
CenterWatch Staff

Chronos Therapeutics, a private biotech company focused on ageing diseases, brain and nervous system disorders, announced that Dr. Huw Jones, CEO of Chronos, has been awarded Best CEO in the European Drug Discovery Industry by online and print magazine European CEO.

Dr. Jones was one of six finalists nominated anonymously for this prestigious award in 2016. The award follows a transformative year for Chronos with several key patents submitted, important preclinical data developing for the company’s lead asset as well as the first acquisition which was concluded in July 2016. The innovative transaction saw Chronos acquiring global rights to three new chemical entity preclinical programs targeting the central nervous system from a subsidiary of Shire with the seller becoming a shareholder in the business in return.

Dr. Huw Jones, CEO of Chronos Therapeutics, said, “This award recognizes Chronos’ team effort in developing and acquiring treatments for patients with degenerative and behavioral diseases. We are developing a re-purposed asset for the devastating disease ALS and actively searching for more discoveries in neurodegeneration. We recently concluded an innovative deal with Shire that adds value to Chronos and has the potential to alleviate significant suffering.”

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing